Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Enfortumab vedotin shows promise as a targeted therapy for advanced urothelial carcinoma, particularly in patients who have previously received platinum-based chemotherapy and an immune-checkpoint inhibitor. The EV-301 phase III trial demonstrated significantly improved overall survival and response rates compared to standard chemotherapy. However, more data, especially from larger real-world studies, are needed to further assess its effectiveness in Japanese patients. METHODS: A total of 6007 urothelial cancer patients inducted with pembrolizumab as a second-line treatment were analyzed. Among them, 563 patients received enfortumab vedotin after pembrolizumab, while 443 patients received docetaxel or paclitaxel after pembrolizumab, and all were included in the study for efficacy as a life prolonging agent. RESULTS: The enfortumab vedotin group showed a longer overall survival than the paclitaxel/docetaxel group (p = 0.013, HR: 0.71). In multivariate analysis, enfortumab vedotin induction was the independent risk factor for overall survival (p = 0.013, HR: 0.70). There were no significant differences in cancer-specific survival. CONCLUSIONS: Enfortumab vedotin prolonged the overall survival for Japanese advanced or metastatic urothelial carcinoma patients compared to paclitaxel or docetaxel after pembrolizumab treatment.

DOI： 10.3390/cancers15174227

PubMed

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Frontiers Media SA  

Introduction: Several healthy euploid births have been reported following the transfer of mosaic embryos, including both euploid and aneuploid blastomeres. This has been attributed to a reduced number of aneuploid cells, as previously reported in mice, but remains poorly explored in humans. We hypothesized that mitochondrial function, one of the most critical factors for embryonic development, can influence human post-implantation embryonic development, including a decrease of aneuploid cells in mosaic embryos.

Methods: To clarify the role of mitochondrial function, we biopsied multiple parts of each human embryo and observed the remaining embryos under in vitro culture as a model of post-implantation development (n = 27 embryos). Karyotyping, whole mitochondrial DNA (mtDNA) sequencing, and mtDNA copy number assays were performed on all pre- and post-culture samples.

Results: The ratio of euploid embryos was significantly enhanced during in vitro culture, whereas the ratio of mosaic embryos was significantly reduced. Furthermore, post-culture euploid and culturable embryos had significantly few mtDNA mutations, although mtDNA copy numbers did not differ.

Discussion: Our results indicate that aneuploid cells decrease in human embryos post-implantation, and mtDNA mutations might induce low mitochondrial function and influence the development of post-implantation embryos with not only aneuploidy but also euploidy. Analyzing the whole mtDNA mutation number may be a novel method for selecting a better mosaic embryo for transfer.

DOI： 10.3389/fcell.2023.1215626

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: Postoperative sleep disturbances are common. Although several studies have examined the effect of melatonin on postoperative sleep disturbances, the results have not reached any definitive conclusion. We sought to conduct a systematic review to compare the effects of melatonin and melatonin agonists on postoperative sleep quality with those of placebo or no treatment in adult patients who underwent surgery under general or regional anesthesia. METHODS: We searched MEDLINE, Cochrane Central Register of Controlled Trials, Embase, Web of Science, ClinicalTrials.gov, and the UMIN Clinical Trials Registry up to 18 April 2022. Randomized clinical trials examining the effects of melatonin or melatonin agonists in patients undergoing general or regional anesthesia with sedation for any surgery were eligible for inclusion. The primary outcome was sleep quality measured using a visual analog scale (VAS). The secondary outcomes were postoperative sleep duration, sleepiness, pain, opioid consumption, quality of recovery, and adverse events. A random-effects model was used to combine the results. We assessed study quality with the Cochrane Risk of Bias Tool version 2. We applied a trial sequential analysis to assess the precision of the combined results. RESULTS: Eight studies (516 participants) were analyzed for sleep quality. Of those, four studies used only a short duration of melatonin, either on the night before and the day of surgery or only on the day of surgery. A random-effects meta-analysis showed that melatonin did not improve sleep quality measured by VAS compared with placebo (mean difference, -0.75 mm; 95% confidence interval, -4.86 to 3.35), with low heterogeneity (I2, 5%). Trial sequential analysis revealed that the accrued information size (n = 516) reached the estimated required information size (n = 295). We downgraded the certainty of the evidence because of the high risk of bias. The effect on postoperative adverse events was comparable between the melatonin and control groups. CONCLUSION: Our results indicate that melatonin supplementation does not improve postoperative sleep quality measured with the VAS compared with placebo in adult patients (GRADE: moderate). STUDY REGISTRATION: PROSPERO (CRD42020180167); registered 27 October 2022.

DOI： 10.1007/s12630-023-02442-1

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

With advances in cancer treatment, such as cytotoxic chemotherapy and radiotherapy, grave new sequelae of treatment have emerged for young cancer survivors. One sequela that cannot be overlooked is male infertility, with reportedly 15% to 30% of cancer survivors losing their fertility potential. Cytotoxic therapy influences spermatogenesis at least temporarily, and in some cases, permanently. The degree of spermatogenesis impairment depends on the combination of drugs used, their cumulative dose, and the level of radiation. The American Society of Clinical Oncology has created an index to classify the risks to fertility based on treatment. Medical professionals currently use this risk classification in fertility preservation (FP) programs. FP programs are currently being promoted to prevent spermatogenesis failure resulting from cancer treatment. For patients who are able to ejaculate and whose semen contains sperm, the semen (sperm) is cryopreserved. Moreover, for patients who lack the ability to ejaculate, those with azoospermia or severe oligozoospermia, and those who have not attained puberty (i.e., spermatogenesis has not begun), testicular biopsy is performed to collect the sperm or germ cells and cryopreserve them. This method of culturing germ cells to differentiate the sperm has been successful in some animal models, but not in humans. FP has recently gained popularity; however, some oncologists and medical professionals involved in cancer treatment still lack adequate knowledge of these procedures. This hinders the dissemination of information to patients and the execution of FP. Information sharing and collaboration between reproductive medicine specialists and oncologists is extremely important for the development of FP. In Japan, the network of clinics and hospitals that support FP is expanding across prefectures.

DOI： 10.5534/wjmh.220102

PubMed

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

DOI： 10.1007/s12630-023-02442-1

researchmap

Other Link： https://link.springer.com/article/10.1007/s12630-023-02442-1/fulltext.html

Language：English   Publishing type：Research paper (scientific journal)  

Introduction: Malignant bone and soft tissue tumors, commonly called sarcomas, predominantly originate in bone and soft tissues and typically affect individuals at a younger age. Following the resection of the primary tumor, treatment often necessitates radiation therapy and gonadotoxic chemotherapy, the specifics of which depend on the disease's stage Conversely, there is a notable concern regarding the potential loss of fertility due to these treatments. Consequently, it is recommended that men consider sperm cryopreservation before initiating treatment. This study aims to assess spermatogenesis in male patients diagnosed with malignant bone and soft tissue tumors before and after chemotherapy. Methods: This study involved 34 male patients diagnosed with malignant bone and soft tissue tumors and subsequently underwent sperm cryopreservation before initiating treatment. Medical records included details about the primary disease, age, marital status at presentation, semen analysis results, treatment regimen and number of courses, post-treatment semen analysis, renewal status and outcomes. Results: The mean age at the time of sperm cryopreservation was 22.8 years. The median semen volume was 2.5 mL, sperm concentration was 32.6 million/ml, and sperm motility was 38.5%. Following chemotherapy, semen analysis was conducted on 12 patients, with ifosfamide being the predominant drug used in all cases. Among these 12 patients, eight retained viable spermatozoa, and two successfully achieved spontaneous pregnancies resulting in live births. In one of the remaining four cases where no sperm were detected in ejaculate, a live birth was achieved through intracytoplasmic sperm injection using cryopreserved sperm. Discussion: While ifosfamide, the primary chemotherapy drug for patients with malignant bone and soft tissue tumors, was associated with severe impairments in spermatogenesis, recovery of spermatogenesis was observed in many cases. However, there were instances of prolonged azoospermia. Even in such cases, assisted reproduction using cryopreserved sperm remained viable for achieving parenthood. In light of these findings, offering patients the opportunity for fertility preservation is advisable.

DOI： 10.3389/fphar.2023.1324339

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

INTRODUCTION: Varicocelectomy is well known to improve the pregnancy outcome of patients with clinical varicoceles in assisted reproductive technologies as well as spontaneous conception. Therefore, this study aimed to evaluate the additional effects of oral antioxidant therapy after varicocelectomy on the pregnancy outcome in the assisted reproductive technology setting. METHODS: This study was a retrospective cohort study. The subjects were couples among whom the male partner had undergone varicocelectomy and was scheduled for subsequent assisted reproductive technology. Pregnancy outcomes were followed retrospectively in 62 couples with male partners who received tocopherol (antioxidant group) and 37 couples who did not (control group). The tocopherol and control groups were assigned dependent on the decision of the physician in charge and the patient's request. The clinical pregnancy rates per couple and embryo transfer, time to pregnancy, and the number of cycles during transfer to pregnancy were evaluated. RESULTS: No significant differences were observed in the pregnancy rate per couple (antioxidant group 70.9% vs. control group 64.9%, P = 0.55) and per embryo transfer (50.4% vs. 39.6%, P = 0.22). Regarding the time to event analyzed by adjusted restricted mean survival time, the mean time to pregnancy was significantly shorter in the antioxidant (tocopherol) group (14.2 vs. 17.4 months, P = 0.025). No significant difference was observed in the embryo transfer cycle to pregnancy (mean embryo transfer cycles: 2.6 vs. 3.0, P = 0.238). CONCLUSIONS: Additional oral tocopherol nicotinate as antioxidant therapy after varicocelectomy was shown to shorten the time to pregnancy. It is recommended that add-on effects be tested in more well-designed randomized controlled trials to examine whether it improves assisted reproductive outcomes.

DOI： 10.3389/frph.2023.1325566

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/iju.15047

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The ALSYMPCA trial revealed radium-223 (Ra-223) to be a life-prolonging agent for bone metastatic castration-resistant prostate cancer (CRPC). However, only 2.8% of enrolled patients in that clinical trial were Asian, and no Japanese patients were enrolled. Several retrospective studies have been published concerning Japanese bone metastatic CRPC patients receiving Ra-223. However, no study has yet reported the correlation between Ra-223 induction and the survival in Japanese bone metastatic CRPC patients. This study investigated the effect of Ra-223 as a life-prolonging agent in a large Japanese healthcare fee database. METHODS: A total of around 410 000 prostate cancer patients were extracted from this database, and 25 934 were diagnosed with CRPC. In these patients, the age, date of the CRPC diagnosis, date of Ra-223 induction, and prognosis were analyzed. RESULTS: A total of 1628 patients received Ra-223, and 6693 patients were diagnosed with bone metastasis CRPC, with the remaining 17 613 patients diagnosed with CRPC without bone metastasis. The patients who completed six courses of Ra-223 showed a significantly more favorable overall and cancer-specific survival than those who received ≤5 courses (p < 0.0001 and p < 0.0001, respectively). For time from CRPC diagnosis date to death, the Ra-223 induction group showed a significantly more favorable prognosis with regard to both the overall and cancer-specific survival than the bone metastatic CRPC patients without Ra-223 (p < 0.0001 and p < 0.0001, respectively). CONCLUSIONS: Bone metastatic CRPC patients who received Ra-223 showed a significantly better prognosis than bone metastatic CPRC patients who did not receive Ra-223.

DOI： 10.1111/iju.15008

PubMed

researchmap

Language：English  

Introduction: We report a case series of six patients with a chief complaint of infertility who underwent microsurgical varicocelectomy for intratesticular varicocele (ITV) after undergoing orchiopexy for undescended testis in their childhood. Case presentation: The patients' median age was 34 years. The median age at which orchiopexy was performed was 4.5 years. All the cases of ITV were accompanied by extratesticular varicocele (ETV). All the patients underwent a microsurgical subinguinal varicocelectomy. At 3 months after operation, the ITV and ETV had disappeared in all the cases. Sperm density and motility increased in five and four patients, respectively. Conclusion: ITV occurs at a relatively high frequency after orchiopexy for undescended testis. Disorder of the valvular function of the testicular vein in peeling the testicular vessels was thought to be a primary cause and is often found on the left side. Doppler ultrasonography of the testis is considered important for diagnosis.

DOI： 10.1002/iju5.12498

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: The success of vasectomy is determined by the outcome of a post-vasectomy semen analysis (PVSA). This article describes a step-by-step procedure to perform PVSA accurately, report data from patients who underwent post vasectomy semen analysis between 2015 and 2021 experience, along with results from an international online survey on clinical practice. MATERIALS AND METHODS: We present a detailed step-by-step protocol for performing and interpretating PVSA testing, along with recommendations for proficiency testing, competency assessment for performing PVSA, and clinical and laboratory scenarios. Moreover, we conducted an analysis of 1,114 PVSA performed at the Cleveland Clinic's Andrology Laboratory and an online survey to understand clinician responses to the PVSA results in various countries. RESULTS: Results from our clinical experience showed that 92.1% of patients passed PVSA, with 7.9% being further tested. A total of 78 experts from 19 countries participated in the survey, and the majority reported to use time from vasectomy rather than the number of ejaculations as criterion to request PVSA. A high percentage of responders reported permitting unprotected intercourse only if PVSA samples show azoospermia while, in the presence of few non-motile sperm, the majority of responders suggested using alternative contraception, followed by another PVSA. In the presence of motile sperm, the majority of participants asked for further PVSA testing. Repeat vasectomy was mainly recommended if motile sperm were observed after multiple PVSA's. A large percentage reported to recommend a second PVSA due to the possibility of legal actions. CONCLUSIONS: Our results highlighted varying clinical practices around the globe, with controversy over the significance of non-motile sperm in the PVSA sample. Our data suggest that less stringent AUA guidelines would help improve test compliance. A large longitudinal multi-center study would clarify various doubts related to timing and interpretation of PVSA and would also help us to understand, and perhaps predict, recanalization and the potential for future failure of a vasectomy.

DOI： 10.5534/wjmh.210191

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: Varicocele is a common problem among infertile men. Varicocele repair (VR) is frequently performed to improve semen parameters and the chances of pregnancy. However, there is a lack of consensus about the diagnosis, indications for VR and its outcomes. The aim of this study was to explore global practice patterns on the management of varicocele in the context of male infertility. MATERIALS AND METHODS: Sixty practicing urologists/andrologists from 23 countries contributed 382 multiple-choice-questions pertaining to varicocele management. These were condensed into an online questionnaire that was forwarded to clinicians involved in male infertility management through direct invitation. The results were analyzed for disagreement and agreement in practice patterns and, compared with the latest guidelines of international professional societies (American Urological Association [AUA], American Society for Reproductive Medicine [ASRM], and European Association of Urology [EAU]), and with evidence emerging from recent systematic reviews and meta-analyses. Additionally, an expert opinion on each topic was provided based on the consensus of 16 experts in the field. RESULTS: The questionnaire was answered by 574 clinicians from 59 countries. The majority of respondents were urologists/uro-andrologists. A wide diversity of opinion was seen in every aspect of varicocele diagnosis, indications for repair, choice of technique, management of sub-clinical varicocele and the role of VR in azoospermia. A significant proportion of the responses were at odds with the recommendations of AUA, ASRM, and EAU. A large number of clinical situations were identified where no guidelines are available. CONCLUSIONS: This study is the largest global survey performed to date on the clinical management of varicocele for male infertility. It demonstrates: 1) a wide disagreement in the approach to varicocele management, 2) large gaps in the clinical practice guidelines from professional societies, and 3) the need for further studies on several aspects of varicocele management in infertile men.

DOI： 10.5534/wjmh.220048

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Klinefelter syndrome and monozygotic twins are both rare. The reports of monozygotic twins with Klinefelter syndrome to have undergone fertility treatment are uncommon. This case report describes a case of 30-year-old monozygotic adult twin brothers diagnosed with nonmosaic Klinefelter syndrome following the complaint of infertility. The result of semen analysis showed cryptozoospermia (very low sperm count) and azoospermia (zero sperm count) with physical findings and lifestyles being very similar. They both underwent microtesticular sperm extraction. One had successful sperm retrieval and achieved pregnancy through intracytoplasmic sperm injection, whereas the other did not. Testicular pathological findings showed Sertoli cell-only syndrome. To the best of our knowledge, this is the first report on monozygotic adult twins both of whom underwent microtesticular sperm extraction and resulted in different outcomes.

DOI： 10.1111/and.14266

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: To evaluate the efficacy of keishibukuryogan, a traditional Kampo formula known to be an anti-Oketsu (impaired microcirculation and non-physiological blood congestion) drug, in combination with an anti-oxidant for the treatment of varicoceles. METHODS: We retrospectively analyzed 119 patients with palpable and subclinical varicoceles who were treated with 7.5 g/day of keishibukuryogan and 600 mg/day of tocopherol nicotinate. Their motile sperm concentrations at the start of medication and after 3 months were compared. As a subgroup analysis, a comparison test was carried out between patients with a high-grade varicocele and those with a low-grade varicocele. RESULTS: The mean age of the study patients was 35.6 years. Among them, 17, 41, 44 and 17 had subclinical, grade 1, grade 2 and grade 3 varicoceles, respectively. Overall, the differences in motile sperm concentration (millions/mL) before and after treatment were not significant (median 0.58, 95% confidence interval -0.12 to 1.56; P = 0.115). The results of the subgroup analysis showed that the motile sperm concentration in patients with a low-grade varicocele significantly increased (median 1.21, 95% confidence interval 0.45-2.47; P = 0.024); however, no significant improvements were seen in patients with a high-grade varicocele. CONCLUSIONS: The results of the present study showed that the combination of keishibukuryogan and an anti-oxidant had a limited effect on varicoceles, but they suggest that it is effective for the treatment of low-grade varicoceles.

DOI： 10.1111/iju.14746

PubMed

researchmap

Language：English  

DOI： 10.4103/aja2021112

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: In this pilot study, the authors compared the effects of antioxidant co-supplementation therapy and methylcobalamin therapy in patients with impaired semen quality. METHODS: Eighty-four subjects who visited male infertility clinics and showed abnormal semen test results were randomly subjected to one of the two therapies: antioxidant co-supplementation therapy with vitamin C, vitamin E, coenzyme Q10, and flaxseed oil or methylcobalamin therapy. The oxidation-reduction potential (ORP) and 8-hydroxy-2'-deoxyguanosine levels were used as indicators of oxidative stress levels in semen. Semen analysis was also performed. RESULTS: The authors obtained results from 67 patients who had completed 3 months of treatment. Neither antioxidant co-supplementation therapy nor methylcobalamin therapy changed the semen parameters significantly (except for the sperm concentration, which was increased by the latter therapy). When the pre-treatment ORP value in semen was higher than the cutoff value, both therapies significantly increased the sperm concentration. The 8-hydroxy-2'-deoxyguanosine level did not yield any meaningful predictive value with regard to increased sperm concentrations. CONCLUSIONS: Both antioxidant co-supplementation therapy and methylcobalamin therapy increased the sperm concentration in patients with impaired semen quality when the basal ORP levels in their semen were elevated.

DOI： 10.1002/rmb2.12450

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Newly emerging serious post-treatment complications among young male cancer survivors involve fertility and sexual function, preventing them from pursuing a normal family life. METHODS: We studied and summarized published studies that assess the relationship between cancer treatments and reduced spermatogenesis or sexual dysfunction. MAIN FINDINGS: Infertility often occurs because of anticancer therapies that impair spermatogenesis. While some patients postremission functionally recover fertility, others experience a decreased sperm count and azoospermia. Fertility-preserving modalities are currently being promoted worldwide to preserve spermatogenesis following cancer therapy. Patients who can ejaculate and have sperm in their semen should cryopreserve semen. However, for patients who have never ejaculated before puberty or in whom spermatogenesis has not been established, testis biopsy is performed to collect and preserve sperm or germ cells. Fertility preservation is gaining popularity and requires continuous information dissemination to oncologists and cancer treatment professionals. Furthermore, male sexual dysfunction predominantly involves erectile dysfunction and ejaculation disorder. CONCLUSION: Although preventive and therapeutic methods for these disorders have been established within urology, patients and medical professionals in other fields remain uninformed of these advances. Therefore, dissemination of information regarding fertility preservation techniques should be accelerated.

DOI： 10.1002/rmb2.12481

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：English  

DOI： 10.1002/iju5.12378

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：English  

DOI： 10.1111/iju.14678

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

INTRODUCTION: The circadian rhythm of melatonin secretion is disturbed after general anaesthesia, leading to postoperative sleep disturbance. Small studies investigating the preventive effect of melatonin administration on postoperative sleep disturbance have not reached any conclusions. Therefore, we will conduct a systematic review and meta-analysis to obtain conclusive results. METHODS AND ANALYSIS: We prepared this protocol following the 2015 Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols guidelines. We will conduct a search for randomised controlled trials that evaluated the effect of melatonin and melatonin agonists on postoperative sleep quality in adult patients undergoing general anaesthesia or regional anaesthesia with sedation. We will exclude patients undergoing regional anaesthesia without sedation. Relevant studies will be searched in the following eight databases: MEDLINE, the Cochrane Central Register of Controlled Trials, Embase, Web of Science and four preregistration sites from inception to 1 January 2021. No language restrictions will be applied. Two authors will independently scan and select eligible studies and perform data extraction and assessment of the risk of bias. The Visual Analogue Scale scores for sleep quality will be combined as the mean difference with a 95% CI using a random-effect model; we will use I2 to assess heterogeneity. We will evaluate the quality of trials using the Cochrane methodology and assess the quality of evidence using the Grading of Recommendation Assessment, Development and Evaluation approach. If appropriate, trial sequential analysis will be performed. ETHICS AND DISSEMINATION: No ethical approval is required for this meta-analysis, as it does not include individual patient data. We will disseminate the results of this meta-analysis in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42020180167.

DOI： 10.1136/bmjopen-2020-047858

PubMed

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Background: Between 30% and 80% of patients with male infertility produce excessive reactive oxygen species (ROS) in their ejaculate even though the cause of male infertility is unexplained in approximately half of cases. The strong connection between oxidative stress (OS) and male infertility has led recent investigators to propose the term "Male Oxidative Stress Infertility (MOSI)" to describe OS-associated male infertility. Methods: We searched the PubMed database for original and review articles to survey the effects of OS on male infertility, and then verified the effects and treatments. Main findings: Seminal plasma contains many antioxidants that protect sperm from ROS, because low amounts of ROS are required in the physiological fertilization process. The production of excessive ROS causes OS which can lower fertility through lipid peroxidation, sperm DNA damage, and apoptosis. Several assays are available for evaluating OS, including the MiOXSYS® analyzer to measure oxidation-reduction potential. Several measures should be considered for minimizing OS and improving clinical outcomes. Conclusion: Accurately diagnosing patients with MOSI and identifying highly sensitive biomarkers through proteomics technology is vital for better clinical outcomes.

DOI： 10.1002/rmb2.12353

PubMed

researchmap

Language：Japanese   Publisher：日本外科系連合学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Background: At present, one out of six couples is infertile, and in 50% of cases, infertility is attributed to male infertility factors. Genetic abnormalities are found in 10%-20% of patients showing severe spermatogenesis disorders, including non-obstructive azoospermia. Methods: Literatures covering the relationship between male infertility and genetic disorders or chromosomal abnormalities were studied and summarized. Main findings Results: Genetic disorders, including Klinefelter syndrome, balanced reciprocal translocation, Robertsonian translocation, structural abnormalities in Y chromosome, XX male, azoospermic factor (AZF) deletions, and congenital bilateral absence of vas deferens were summarized and discussed from a practical point of view. Among them, understanding on AZF deletions significantly changed owing to advanced elucidation of their pathogenesis. Due to its technical progress, AZF deletion test can reveal their delicate variations and predict the condition of spermatogenesis. Thirty-nine candidate genes possibly responsible for azoospermia have been identified in the last 10 years owing to the advances in genome sequencing technologies. Conclusion: Genetic testing for chromosomes and AZF deletions should be examined in cases of severe oligozoospermia and azoospermia. Genetic counseling should be offered before and after genetic testing.

DOI： 10.1002/rmb2.12336

PubMed

researchmap

Language：English  

Introduction: Post-orgasmic illness syndrome is a rare condition that occurs after ejaculation and persists for 2-7 days and is characterized by flu-like symptoms, which can significantly reduce quality of life. Case presentation: A 21-year-old unmarried man was referred to our hospital due to flu-like symptoms that developed after ejaculation by masturbation and persisted for about 2 days. The patient's free testosterone level was slightly lower than normal. Nonsteroidal anti-inflammatory drugs were initially administered and helped relieve headache and muscle pain. Thereafter, the patient was able to ejaculate three times a week. In addition, after administering testosterone enanthate once or twice a month, his general fatigue significantly improved, and he could ejaculate every day. Conclusion: The pathophysiology of post-orgasmic illness syndrome has not been fully elucidated. The treatments for this condition must be accurately selected according to pathophysiology.

DOI： 10.1002/iju5.12184

PubMed

researchmap

Language：Japanese   Publisher：金原出版(株)  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00535&link_issn=&doc_id=20200602180012&doc_link_id=10.18888%2Fsp.0000001272&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fsp.0000001272&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

Language：Japanese   Publisher：(株)医学書院  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J01564&link_issn=&doc_id=20200619060015&doc_link_id=10.11477%2Fmf.1409210067&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1409210067&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Advanced treatments have improved the prognosis of cancer survivors. Anticancer drugs generate large amounts of cellular reactive oxygen species (ROS), but their direct effects on sperm ROS production are unclear. We examined 64 semen samples of men who had received cancer chemotherapy, 467 semen samples of men consulting for idiopathic infertility, and 402 semen samples of partners of female patients as a control group. ROS production was calculated as the integrated chemiluminescence between 0 and 200 seconds after the addition of luminol to unwashed semen. We found that their ROS-positive rate of semen samples in the chemotherapy group was significantly higher than that in the control group. We compared the sperm parameters (concentration and motility) and the ROS production levels between chemotherapy subgroups and one of the remaining subgroups with positive ROS, and we found that only sperm motility was significantly lower in the samples in the postchemotherapy subgroup than in the idiopathic infertility subgroup, and that both sperm parameters were significantly lower in those from postchemotherapy subgroup than in the control subgroup. The ROS production level per million spermatozoa in the postchemotherapy subgroup was significantly higher than that in the control subgroup. Additionally, we compared variables, such as age, sperm features, and the duration from the end of the treatment to the first consultation between ROS-positive and ROS-negative subgroups in samples from men in the postchemotherapy group, but we found no significant differences. Of the men in the postchemotherapy group, three underwent a long-term antioxidant therapy, and all of them had low ROS semen levels after that. In conclusion, the production of ROS in semen detected by chemiluminescence from men who undergo cancer chemotherapy is similar to that of men with idiopathic infertility, and long-term oral antioxidant therapy may reduce the amount of ROS in the semen.

DOI： 10.3390/antiox8100449

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

DOI： 10.1016/j.fertnstert.2019.07.484

Web of Science

researchmap

Language：Japanese  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(一社)日本性機能学会  

researchmap

Language：English  

Introduction: Iatrogenic ureteral injury is sometimes seen in daily clinical practice, and gynecological surgery carries the highest risk of ureteral injury among iatrogenic surgical ureteral injury. Case presentation: A 61-year-old woman was referred to our department for right ureteral stricture and hydronephrosis after total hysterectomy. We initially attempted ureteral stenting, but hydronephrosis redeveloped 1 month after ureteral stent removal. We performed ureteroscopy via an antegrade approach and successfully incised and dilated the ureter. Conclusion: We encountered a case of severe ureteral stenosis after total hysterectomy that was successfully treated endoscopically using ureteroscopy via an antegrade approach.

DOI： 10.1002/iju5.12061

PubMed

researchmap

DOI： 10.1159/000501716

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: Urethral stenosis is a disease in which the lumen of the urethra becomes constricted by fibrosis. Such stenoses have been treated by urethral dilation using a bougie and optical internal urethrotomy (OIU). Recently, high-pressure balloon dilation (BD) has been developed as a new treatment method for urethral stenosis. The present study compared the effectiveness of urethral dilation by BD and OIU. METHODS: Twenty-two patients of urethral stenosis were treated at Yokohama City University Medical Center between 2005 and 2015. Of these, 13 underwent BD, whereas OIU was performed in 9. BD was performed at 30 atm twice for 5 min each time. In OIU, an endoscopic knife was used to cut out the stenotic lesion in 3 directions. The endpoint was set as restenosis, which required additional surgical treatment, including BD, OIU, and the use of a urethral bougie. RESULTS: The causes of urethral stricture were endoscopic surgery (n = 7; 31.8%), development after total prostatectomy (n = 4; 18.2%), iatrogenic reasons associated with catheter insertion (n = 5; 22.7%), development after a prostate needle biopsy (n = 3; 13.6%), and unknown (n = 3; 13.6%). The site of the stenotic lesion site was the anastomosis (n = 3; 13.6%), bladder neck (n = 6; 27.3%), prostatic urethra (n = 4; 18.2%), anterior urethra (n = 7; 31.8%), and membranous urethra (n = 2; 9.1%). The stenosis-free rate was 84% for those undergoing BD and 22% for those receiving OIU. The median stenosis-free time was significantly longer after BD than OIU (1675 vs. 244 days, respectively; P < .01). CONCLUSION: The stenosis-free time was significantly longer after BD than OIU.

DOI： 10.1111/luts.12208

PubMed

researchmap

Language：English  

Introduction: Testicular epidermal cysts in Klinefelter syndrome are very rare. We report a case of Klinefelter syndrome associated with a testicular epidermal cyst. To our knowledge, this is the first report showing successful spermatozoa retrieval from the affected testis. Case presentation: A 25-year-old married man was referred to our hospital with right scrotal induration, which was in lower pole of the right testis. Testicular cancer tumor markers were normal; endocrinological findings indicated hypergonadotropic hypogonadism. Semen analyses revealed azoospermia. Preoperative chromosome test result: 47, XXY karyotype; ultrasonography report: 1.9-cm internal heterogeneous echoic mass in the right testis (malignancy not discarded). Because the patient hoped for children, he underwent high orchiectomy with ipsilateral testicular sperm extraction (200 spermatozoa from normal testicular tissue) for future fertilization procedures. Tumor pathology was an epidermal cyst. Conclusion: While performing orchiectomy for testicular tumors, sperm retrieval should be attempted from normal tissues in patients planning for children.

DOI： 10.1002/iju5.12037

PubMed

researchmap

Language：Japanese   Publisher：(公社)神奈川県医師会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Institute of Electrical Engineers of Japan  

DOI： 10.1541/ieejeiss.139.1461

Scopus

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Bentham Science Publishers B.V.  

DOI： 10.2174/1874303X01912010001

Scopus

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Blackwell Publishing Ltd  

DOI： 10.1111/and.13024

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Oxidative stress is a primary cause of vascular endothelial damage. In the prostate, ischemia increases the levels of reactive oxygen species, growth factors and cytokines, and induces the development of angiogenesis, which results in cancer progression. The expression levels of an oxidative stress marker, 8-hydroxyguanosine (8-OHdG), were compared between prostate cancer and non-neoplastic prostate tissues. A prostate tissue microarray composed of 10 cases of prostatic adenocarcinoma and 70 cases of benign prostatic hyperplasia was immunohistochemically stained for 8-OHdG. All cases expressed 8-OHdG. The levels of 8-OHdG expression in prostatic cancer (30.0% moderate and 70.0% strong) were significantly higher than those in benign prostatic hyperplasia (71.4% moderate and 28.6% strong; (p<0.01). Notably, 8-OHdG is expressed more highly in prostate cancer tissues in comparison to benign prostate tissues.

DOI： 10.3892/mco.2018.1665

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Aspergillosis in patients with impaired immunity usually presents with invasive pulmonary infection and dissemination to a variety of organs via hematogenous spread. Aspergilloma in the retroperitoneal cavity is a rare disease with only a few cases reported in the literature. To the best of our knowledge, the present case of a retroperitoneal aspergilloma with no surgical history is only the second report in the literature. CASE PRESENTATION: A 65 year-old man, who had been receiving immunosuppressive treatment for rheumatoid arthritis with vasculitis for 9 years, was referred to the Urology Department with a retroperitoneal mass. This was confirmed by computed tomography performed during treatment for pulmonary aspergilloma. Because it was not possible to rule out malignant disease (e.g., liposarcoma), surgical exploration was performed. Pathological examination revealed aspergillus hyphae with fat necrosis, and retroperitoneal aspergilloma was diagnosed and appropriately treated. The tumor did not recur subsequently. CONCLUSION: Our present case emphasizes that pharmacological treatments for aspergilloma in the retroperitoneal cavity have poor drug transitivity, so the relative effectiveness of pharmacological response is not useful for differentiating retroperitoneal aspergilloma from malignant disease.

DOI： 10.1186/s12894-018-0381-0

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Korean Society for Reproductive Medicine  

DOI： 10.5653/cerm.2018.45.1.44

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Korean Society for Reproductive Medicine  

DOI： 10.5653/cerm.2018.45.1.48

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：S. Karger AG  

DOI： 10.1159/000487389

Scopus

researchmap

Language：English   Publishing type：Research paper (international conference proceedings)   Publisher：IEEE  

This research aims to realize sperm selection support system for assisted reproductive technology. Sperm detection is one of the important component technology. High detection rate is required even the expense of false positive detections so as not to miss promising sperms as much as possible. False positive rate control is key technology for assure high detection rate and adaptive threshold adjustment methods in boosting is proposed. Our experiments evaluate and compare adaptive thresholding method and normal thresholding method as for detection rate and false positive rate of sperm detection.

DOI： 10.1109/SMC.2018.00339

Web of Science

researchmap

Publishing type：Research paper (international conference proceedings)   Publisher：IEEE  

DOI： 10.1109/SMC.2018.00339

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：BioMed Central Ltd.  

DOI： 10.1186/s13256-017-1473-2

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Ediciones Doyma, S.L.  

DOI： 10.1016/j.androl.2017.09.001

Scopus

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：John Wiley and Sons Ltd  

DOI： 10.1002/rmb2.12052

Scopus

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(公社)神奈川県医師会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.androl.2016.08.002

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1080/19396368.2017.1294214

Web of Science

PubMed

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：BioMed Central Ltd.  

DOI： 10.1186/s13256-017-1303-6

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.4103/1008-682X.173933

Web of Science

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：S. Karger AG  

DOI： 10.1159/000445826

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Editorial Board of Acta Urologica Japonica  

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Editorial Board of Acta Urologica Japonica  

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Editorial Board of Acta Urologica Japonica  

Scopus

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Editorial Board of Acta Urologica Japonica  

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Editorial Board of Acta Urologica Japonica  

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Editorial Board of Acta Urologica Japonica  

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

Scopus

PubMed

researchmap

Language：Japanese   Publisher：泌尿器科紀要刊行会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J01269&link_issn=&doc_id=20121005420004&doc_link_id=40019429492&url=https%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F40019429492&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

Language：Japanese   Publishing type：Research paper (scientific journal)  

Scopus

PubMed

researchmap

Language：Japanese   Publisher：泌尿器科紀要刊行会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J01269&link_issn=&doc_id=20120809420007&doc_link_id=40019362516&url=https%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F40019362516&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

Language：Japanese   Publishing type：Research paper (scientific journal)  

Scopus

PubMed

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

Scopus

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

Scopus

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(公社)神奈川県医師会  

researchmap

Language：Japanese   Publisher：一般社団法人 日本泌尿器科学会  

DOI： 10.5980/jpnjurol.99.443_2

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本性機能学会  

researchmap

Language：Japanese   Publisher：日本遺伝カウンセリング学会  

researchmap

Language：Japanese   Publisher：金原出版(株)  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J00535&link_issn=&doc_id=20190626060017&doc_link_id=10.18888%2Fsp.0000000886&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fsp.0000000886&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(NPO)日本がん・生殖医療学会  

researchmap

Language：Japanese   Publisher：金原出版(株)  

researchmap

Language：English  

DOI： 10.1016/j.androl.2017.09.001

Web of Science

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：国立病院総合医学会  

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：泌尿器科紀要刊行会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：金原出版(株)  

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2014393480

Language：Japanese   Publisher：泌尿器科紀要刊行会  

researchmap

Language：Japanese   Publisher：泌尿器科紀要刊行会  

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：泌尿器科紀要刊行会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(株)医学書院  

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2012040979

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：神奈川県医師会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(株)医学書院  

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2010307045

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Language：Japanese   Publisher：神奈川県医師会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会  

DOI： 10.5980/jpnjurol.99.395_1

researchmap

Language：Japanese   Publisher：神奈川県医師会  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Poster presentation  

researchmap

Presentation type：Oral presentation (invited, special)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Poster presentation  

researchmap

Presentation type：Oral presentation (invited, special)  

researchmap

Presentation type：Poster presentation  

researchmap

Presentation type：Poster presentation  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Poster presentation  

researchmap

Presentation type：Poster presentation  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Language：English  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

researchmap

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Poster presentation  

researchmap

researchmap

researchmap

researchmap